TP53 and cancer: The aim of these inhibitors is to specifically target cancer cells on the basis that only p53-mutant cancers, which rely on Wee1 to maintain the DNA damage checkpoint in G2, will be sensitive to Wee1 inhibitors (Hirai et al., 2009; Otto and Sicinski, 2017).